SEC Form 4 · accession 0001104659-16-108195

Corvus Pharmaceuticals, Inc. · CRVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Terry P Gould

Director · 10% Owner

Period of report

Mar 29, 2016

Accepted (ET)

Mar 29, 2016 · 11:39 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001626971

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.0001 par value^F1,F2	Mar 29, 2016	C	550,864	—	A	550,864	I	By Fund
Common Stock, $0.0001 par value^F1,F2	Mar 29, 2016	C	92,278	—	A	643,142	I	By Fund
Common Stock, $0.0001 par value^F2	Mar 29, 2016	P	51,712	$15.00	A	694,854	I	By Fund
Common Stock, $0.0001 par value^F1,F3	Mar 29, 2016	C	567,121	—	A	567,121	I	By Fund
Common Stock, $0.0001 par value^F1,F3	Mar 29, 2016	C	95,001	—	A	662,122	I	By Fund
Common Stock, $0.0001 par value^F3	Mar 29, 2016	P	53,239	$15.00	A	715,361	I	By Fund
Common Stock, $0.0001 par value^F1,F4	Mar 29, 2016	C	428,998	—	A	428,998	I	By Fund
Common Stock, $0.0001 par value^F1,F4	Mar 29, 2016	C	71,863	—	A	500,861	I	By Fund
Common Stock, $0.0001 par value^F4	Mar 29, 2016	P	40,272	$15.00	A	541,133	I	By Fund
Common Stock, $0.0001 par value^F1,F5	Mar 29, 2016	C	583,510	—	A	583,510	I	By Fund
Common Stock, $0.0001 par value^F1,F5	Mar 29, 2016	C	97,746	—	A	681,256	I	By Fund
Common Stock, $0.0001 par value^F5	Mar 29, 2016	P	54,777	$15.00	A	736,033	I	By Fund

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Convertible Preferred Stock^F1,F2,F6	—	Mar 29, 2016	C	550,864	D	—	—	Common Stock	550,864	I
Series B Convertible Preferred Stock^F1,F2,F6	—	Mar 29, 2016	C	92,278	D	—	—	Common Stock	92,278	I
Series A Convertible Preferred Stock^F1,F3,F6	—	Mar 29, 2016	C	567,121	D	—	—	Common Stock	567,121	I
Series B Convertible Preferred Stock^F1,F3,F6	—	Mar 29, 2016	C	95,001	D	—	—	Common Stock	95,001	I
Series A Convertible Preferred Stock^F1,F4,F6	—	Mar 29, 2016	C	428,998	D	—	—	Common Stock	428,998	I
Series B Convertible Preferred Stock^F1,F4,F6	—	Mar 29, 2016	C	71,863	D	—	—	Common Stock	71,863	I
Series A Convertible Preferred Stock^F1,F5,F6	—	Mar 29, 2016	C	583,510	D	—	—	Common Stock	583,510	I
Series B Convertible Preferred Stock^F1,F5,F6	—	Mar 29, 2016	C	97,746	D	—	—	Common Stock	97,746	I

Explanation of responses

F1The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering.
F2Represents shares held directly by Adams Street 2011 Direct Fund LP ("AS 2011"). Adams Street Partners, LLC, as the managing member of the general partner of the general partner of AS 2011, may be deemed to beneficially own the shares held by AS 2011. Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by AS 2011. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert disclaim beneficial ownership of the shares held by AS 2011 except to the extent of their pecuniary interest therein.
F3Represents shares held directly by Adams Street 2012 Direct Fund LP ("AS 2012"). Adams Street Partners, LLC, as the managing member of the general partner of the general partner of AS 2012, may be deemed to beneficially own the shares held by AS 2012. Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by AS 2012. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert disclaim beneficial ownership of the shares held by AS 2012 except to the extent of their pecuniary interest therein.
F4Represents shares held directly by Adams Street 2013 Direct Fund LP ("AS 2013"). Adams Street Partners, LLC, as the managing member of the general partner of the general partner of AS 2013, may be deemed to beneficially own the shares held by AS 2013. Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by AS 2013. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert disclaim beneficial ownership of the shares held by AS 2013 except to the extent of their pecuniary interest therein.
F5Represents shares held directly by Adams Street 2014 Direct Fund LP ("AS 2014"). Adams Street Partners, LLC, as the managing member of the general partner of the general partner of AS 2014, may be deemed to beneficially own the shares held by AS 2014. Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by AS 2014. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray, David S. Welsh and Michael R. Zappert disclaim beneficial ownership of the shares held by AS 2014 except to the extent of their pecuniary interest therein.
F6The expiration date is not relevant to the conversion of these securities.
F7AS 2011, AS 2012, AS 2013 and AS 2014 purchased an aggregate of 200,000 shares of Issuer's common stock in connection with the initial public offering at the offering price of $15.00 per share.